(人民日报健康客户端记者 ...
20 小时
金融界财经 on MSN礼来降低小瓶装减肥药Zepbound价格 以打击仿制药美国医药巨头礼来正在加大对廉价 Zepbound 仿制品的打击力度,该公司在官网宣布,将降低畅销减肥药Zepbound“小瓶装”的价格。 据一份声明称,该公司将把 2.5 毫克和 5 毫克 Zepbound 药瓶的价格分别降至每月 349 美元和 ...
Zepbound 2.5毫克和5毫克规格的小瓶装产品月度价格将分别降至349美元和499美元,较此前降低约50美元。在过去,由于减肥药供给不足,患者们不得不转而使用那些价格更便宜的复合仿制药。
智通财经APP获悉,礼来公司 (LLY.US)于美东时间周四盘前公布第四季度财报及全年业绩报告。鉴于对其广受欢迎的糖尿病和减肥药物在新市场的推出充满希望,公司年度盈利指引远高于华尔街预期。
今年1月中旬,这家生产减肥药物Zepbound的制造商下调了第四季度的收入预期,原因是其GLP-1药物的销售增速低于预期。这一警告紧随10月份令人失望的第三季度业绩之后,导致其股价在几个月内表现波动。自年初以来,Eli Lilly股价试图重拾动力,上涨了9%。然而,周二收盘时,其股价较去年8月底创下的52周高点972.53美元仍低15%。当时,许多人认为该公司有望达到1万亿美元的估值。
Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...
The latest weight-loss drugs including Ozempic, Wegovy, Mounjaro, and Zepbound have list prices ranging from $900 to $1,500 for a one-month supply. David Ricks, the CEO of Mounjaro and Zepbound ...
Eli Lilly's weight-loss drugs include Mounjaro and Zepbound.Sandy Huffaker for The Washington Post/Getty Images Weight-loss drugs such as Ozempic and Zepbound cost $900 to $1,500 for a month's supply.
20 天
来自MSN礼来Q4业绩喜忧参半:盈利超预期 减肥药销售连续两季未达预期财联社2月6日讯(编辑 夏军雄)美东时间周四盘前,美国制药巨头礼来公司公布了喜忧参半的四季度财报,该公司盈利超出华尔街的预期,但替尔泊肽(Tirzepatide)的销售额低于预期。
Higher volumes of drugs like Mounjaro, Zepbound, Verzenio, Jardiance and Taltz were partially offset by lower sales of Trulicity. Lilly’s new products also contributed to sales growth.
The program includes a 30-minute video chat with a licensed and board certified doctor who can write you a prescription for Mounjaro if appropriate. Ro offers Zepbound, which contains the same ...
The update about the popular semaglutide injections from drug manufacturer Novo Nordisk follows just two months after the FDA said that shortages of tirzepatide injections Zepbound and Mounjaro ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果